Inclusion Criteria:

- Patients must have locally advanced (unresectable) or metastatic, well or moderately
differentiated pancreatic endocrine tumors.

- Measurable disease on CT scan or MRI.

- Age ≥ 18 years and ≤ 80 years.

- Use of effective means of contraception (men and women) in subjects of child-bearing
potential

- Adequate renal function (serum creatinine ≤1.5, urine protein:creatinine ratio <1.0
or urine dipstick for proteinuria < 2+ (patients discovered to have ≥ 2+ proteinuria
on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must
demonstrate ≤ 1 g of protein in 24 hours to be eligible).

- Adequate hepatic function (bilirubin ≤2.0, AST and ALT ≤ 3x ULN.

- Adequate hematologic function (WBC ≥ 3,000, ANC ≥ 1500, platelets ≥ 100,000)

Exclusion Criteria:

- Prior therapy with fluorouracil, doxorubicin, streptozocin or avastin

- Ejection fraction on MUGA <50%

- ECOG performance status > 2

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study other than a Genentech-sponsored avastin
cancer study

- Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or
diastolic blood pressure > 100 mmHg on antihypertensive medications)

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- Unstable angina

- New York Heart Association (NYHA) Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to study
enrollment

- History of stroke or transient ischemic attack within 6 months prior to study
enrollment

- Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

- Symptomatic peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Presence of central nervous system or brain metastases

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 0, anticipation of need for major surgical procedure during the course
of the study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

- Pregnant (positive pregnancy test) or lactating. Use of effective means of
contraception (men and women) in subjects of child-bearing potential

- Proteinuria at screening as demonstrated by either

- Urine protein: creatinine (UPC) ratio ≥ 1.0 at screening OR

- Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria
on dipstick urinalysis at baseline should undergo a 24 hour urine collection and
must demonstrate ≤ 1g of protein in 24 hours to be eligible).

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to Day 0

- Evidence of duodenal invasion on CT scan, MRI, or endoscopy

- Known hypersensitivity to any component of avastin

- Serious, non-healing wound, ulcer, or bone fracture

- Inability to comply with study and/or follow-up procedures